Introduction
============

Prostate cancer is currently one of the most common malignant tumors in men aged \>50 years. The global age-standardized incidence rate of prostate cancer in 2008 was \~30/100,000 individuals, which is second only to that of lung cancer ([@b1-mco-0-0-906]). Screening for prostate cancer mostly relies on digital rectal examination, measurement of prostate-specific antigen (PSA) level, magnetic resonance imaging (MRI) and ultrasound (US). The current standard for diagnosing prostate cancer in men at risk relies on a transrectal US (TRUS)-guided biopsy test, which is blind to cancer location. This method has the advantages of speed, ease, cost-effectiveness, availability and portability, and it is more suitable for wide-area sampling of the prostate, including the far-lateral peripheral zones ([@b2-mco-0-0-906]). However, despite an increasing number of biopsy cores being included in TRUS-guided biopsy protocols, the current standard of including 10--14 randomized cores lacks sensitivity and frequently detects clinically insignificant disease ([@b3-mco-0-0-906]--[@b5-mco-0-0-906]).

It was recently suggested that targeted biopsies of suspicious lesions detected by multi-parametric (mp)-MRI may increase the diagnostic accuracy of TRUS-guided biopsy ([@b6-mco-0-0-906]). mp-MRI combines T2-weighted images with diffusion-weighted images and dynamic contrast enhancement ([@b7-mco-0-0-906],[@b8-mco-0-0-906]). This method exhibits increased sensitivity and specificity and has become the standard imaging technique for biopsy guidance ([@b9-mco-0-0-906],[@b10-mco-0-0-906]). As mp-MRI and biopsy are performed on different days, with the latter commonly performed using a TRUS probe, a number of devices that use image-fusion software have been developed to overlay the suspicious area on mp-MRI onto the US images at the time of biopsy ([@b11-mco-0-0-906]).

In the present study, a meta-analysis of data extracted from published studies using MRI-US image fusion targeted prostate biopsy was performed to assess the accuracy of prostate cancer detection compared with that of systematic biopsy.

Materials and methods
=====================

### Literature search strategy

A literature search was conducted through the PubMed, EMBASE and China National Knowledge Infrastructure databases for studies published prior to July 21st, 2015, using the key words ('prostate cancer', 'prostate neoplasm' or 'prostate') in combination with ('magnetic resonance imaging', 'MRI' or 'MR') and ('transrectal ultrasound' or 'TRUS') and ('fusion', 'registration', 'targeted', 'target', 'computer' or 'software'). Only articles written in English or Chinese and studies on human subjects were included. In addition, references of relevant articles were manually searched to identify potentially eligible studies.

### Eligibility criteria

Two authors assessed each identified study independently. The inclusion of individual studies required that software-based MRI-US fusion targeted prostate biopsies and systematic biopsies had been performed within the same study. In addition, each study was required to contain overall or significant cancer detection results for the two modalities. To allow for a valid comparison, only studies directly comparing the two techniques were included. When multiple studies contained overlapping data, only the most informative study was included. Meeting abstracts, editorials, case reports, letters and reviews were excluded.

### Data extraction

Two investigators blinded to each others\' results independently reviewed the full manuscripts of the eligible studies. The information extracted from each study included first author, year of publication, study design, population (sample size, age, PSA, prostate volume and prior biopsy), type of anaesthesia, systematic biopsy (number of cores and sampling route), MRI-US image fusion targeted biopsy procedure (software used, sampling route, time flow and number of cores per lesion) and separate histological outcomes for systematic vs. targeted biopsy (overall detection rate of cancer and detection rate of clinically significant and insignificant cancer). Disagreements between the two reviewers were resolved through discussion.

### Statistical analysis

All the analyses were performed using the statistical Stata software, version SE/12 (StataCorp LP, College Station, TX, USA). The main outcome was the detection rate of overall prostate cancer and the secondary outcomes were the detection rates of clinically significant and insignificant disease by MRI-TRUS image fusion targeted biopsy compared with the systematic biopsy technique. The definition used to determine clinical significance was that used by each individual study. Fixed-effects or random-effects meta-analysis was performed to pool the original studies on the basis of their relative risk (RR), depending on the result of the heterogeneity analysis. Forest plots were created to summarize all studies, the pooled estimate and corresponding 95% confidence intervals (95% CIs) in a single overview.

Heterogeneity was assessed using the I^2^ statistical method, with I^2^\>50% indicating significant heterogeneity. When heterogeneity was confirmed, a sensitivity analysis was performed by successively excluding each individual study. Subgroup analysis was performed according to several characteristics. Publication bias was assessed using Begg\'s funnel plot and Egger\'s test. All the P-values were two-tailed and P\<0.05 was considered to indicate statistically significant differences.

Results
=======

### Study selection and characteristics

Of the 800 articles retrieved during the initial search, 21 ([@b2-mco-0-0-906],[@b12-mco-0-0-906]--[@b31-mco-0-0-906]) met the inclusion criteria. A flow chart of the study selection process is presented in [Fig. 1](#f1-mco-0-0-906){ref-type="fig"}.

A total of 3,415 patients were included, with a sample size ranging from 20 to 1,003 patients. The majority of studies originated from 6 countries, with studies from the USA comprising the largest proportion (n=10). A total of 6 studies had been conducted on biopsy-naive patients, 4 on patients with a previous negative prostate biopsy, and 11 studies reported on a mixed cohort (either biopsy-naive patients, or those having undergone previous prostate biopsy). All mp-MRI scans had been performed on either a 1.5- or a 3-T scanner and 9 different image fusion platforms currently used in the clinical setting to perform MRI-TRUS targeted biopsies were identified in this meta-analysis. The standard comparator was a 8- to 12-core TRUS biopsy in 18 studies, whereas 3 other studies used transperineal template biopsies, or a combination of the two. The characteristics of the included studies are summarized in [Table I](#tI-mco-0-0-906){ref-type="table"}.

### Overall prostate cancer detection

Details regarding diagnostic criteria and detection ratios in the individual studies are presented in [Table II](#tII-mco-0-0-906){ref-type="table"}. Across the 21 studies, the prevalence of prostate cancer was 63.0% (2,153/3,415). MRI-US fusion biopsy detected overall prostate cancer in 1,562 of 3,315 patients and systematic biopsy in 1,496 of 3,313 patients, resulting in an RR of 1.09 (95% CI: 1.00--1.18; P=0.047) ([Fig. 2](#f2-mco-0-0-906){ref-type="fig"}). The heterogeneity among these studies was moderate (I^2^=47.8%; χ^2^=38.34; P=0.047). Publication bias in this overall analysis was revealed by the Begg\'s funnel plot (P=0.205, Begg\'s test; P=0.017, Egger\'s test) ([Fig. 3](#f3-mco-0-0-906){ref-type="fig"}).

### Clinically significant prostate cancer detection

A total of 14 studies including 1,884 patients were eligible for inclusion in the analysis. The prevalence of clinically significant and insignificant prostate cancer was 47.2% (890/1,884) and 16.6% (313/1,884), respectively. Clinically significant prostate cancer was diagnosed in 721 of the 1,795 patients with MRI-US fusion biopsy compared with 608 of 1,793 patients with systematic biopsy, with an RR of 1.22 (95% CI: 1.06--1.40; P=0.005) ([Fig. 4](#f4-mco-0-0-906){ref-type="fig"}). However, heterogeneity was observed among these studies (I^2^=56.7%; χ^2^=30.04; P=0.005). Begg\'s funnel plots revealed little publication bias in this analysis ([Fig. 5](#f5-mco-0-0-906){ref-type="fig"}), whereas the Egger\'s and Begg\'s tests indicated there was no publication bias.

The results of the subgroup analysis for clinically significant prostate cancer detection are presented in [Table III](#tIII-mco-0-0-906){ref-type="table"}. MRI-US fusion biopsy exhibited a significantly higher detection rate of clinically significant prostate cancer compared with systematic biopsy in 7 subgroups, but there was heterogeneity in all subgroups apart from that of patients with a previous negative biopsy.

Sensitivity analysis of the 14 studies demonstrated that the results of Kuru *et al* ([@b28-mco-0-0-906]) diverged from those of most other trials ([Fig. 6](#f6-mco-0-0-906){ref-type="fig"}). Following exclusion of the Kuru *et al* trial, there was no significant variation in the RR value, but the heterogeneity decreased ([Table IV](#tIV-mco-0-0-906){ref-type="table"}).

Clinically insignificant prostate cancer was diagnosed in 178 of 1,795 patients by MRI-US fusion biopsy and in 256 of 1,793 patients by systematic biopsy, resulting in a RR of 0.73 (95% CI: 0.51--1.05; P=0.089); there was high heterogeneity among these studies (I^2^=67.5%; χ^2^=39.97; P\<0.01).

Discussion
==========

The current gold standard technique for diagnosing prostate cancer in men at risk is systematic prostate biopsy using TRUS. However, there are discrepancies between the results of systematic prostate biopsy and radical prostatectomy specimens ([@b32-mco-0-0-906]), as only 24--40% of TRUS-guided biopsy results are consistent with the pathological findings following prostatectomy ([@b33-mco-0-0-906]). Furthermore, systematic biopsy may not be able to detect all cases of clinically significant prostate cancer, which may delay the treatment of a tumor with a high Gleason score ([@b3-mco-0-0-906]--[@b5-mco-0-0-906]). The optimal biopsy strategy should selectively detect clinically significant prostate cancer and minimize clinically insignificant prostate cancer detection to avoid consequent overtreatment. The present meta-analysis demonstrated that MRI-US fusion targeted biopsy may be a promising strategy with certain advantages over systematic biopsy.

The results of the present study demonstrated that the overall prostate cancer detection rate of MRI-US fusion biopsy is higher compared with that of systematic biopsy, with an RR of 1.09. The difference between the results of the present study and those of a prior systematic review ([@b34-mco-0-0-906]) may be due to the larger sample size and updated data included herein.

It was reported that mp-MRI exhibits a high diagnosis rate of clinically significant prostate cancer when compared to the histological findings following radical prostatectomy ([@b35-mco-0-0-906]), which is in line with the results of the present study. In our study, MRI-US fusion biopsy had an RR of 1.22 for detecting significant prostate cancer, which means that MRI-US fusion biopsy has a 22% increased detection rate for clinically significant prostate cancer compared with systematic biopsy.

MRI-US fusion biopsy and systematic biopsy did not significantly differ in the detection of clinically insignificant prostate cancer; however, an RR of 0.73 indicated that MRI-US had a better performance in terms of avoiding detection of insignificant prostate cancer compared with systematic biopsy in most studies. Thus, the application of MRI-US fusion biopsy may help reduce oversampling of potentially insignificant prostate cancers.

Several studies also compared MRI-US fusion with the systematic approach on a per-core basis ([@b13-mco-0-0-906],[@b21-mco-0-0-906],[@b30-mco-0-0-906]). The results demonstrated that MRI-US-guided biopsy required fewer cores for successful tumor detection, thereby reducing patient discomfort compared with systematic biopsy.

The present meta-analysis had several limitations that may reduce the strength of the conclusions. Studies with negative results are less likely to be published, which may result in the overstatement of beneficial effects in meta-analyses. In the analysis of the overall prostate cancer detection rate, Begg\'s test yielded a P-value of 0.205, while Egger\'s test yielded a P-value of 0.017, indicating the presence of publication bias, as Egger\'s test has a higher sensitivity.

In the analysis of the detection of clinically significant prostate cancer, Begg\'s test and Egger\'s test indicated no publication bias. However, significant heterogeneity was found in this analysis (I^2^=56.7%). Subgroup analysis revealed the presence of heterogeneity in all subgroups apart from that including patients with a previous negative biopsy, indicating that the heterogeneity originated in the category of prior biopsy, but not study design, main race, strength of magnetic field or sampling method. The sensitivity analysis revealed that, after excluding the trial by Kuru *et al* ([@b28-mco-0-0-906]), heterogeneity was markedly decreased, while the RR value was not significantly affected. Kuru *et al* ([@b28-mco-0-0-906]) obtained a higher RR compared with that of the other studies, possibly due to the BiopSee system used in their study, in which US, TRUS/MRI fusion, biopsy planning, perineal targeting, 3D mapping and automated documentation are integrated into a single system. The definition of significant prostate cancer, which included intermediate or high-risk tumors according to the National Comprehensive Cancer Network criteria ([@b36-mco-0-0-906]), may also explain their higher RR. In addition, significant heterogeneity may be attributed to the variability across the studies in terms of criteria for defining clinically significant tumors, the methodology of targeted biopsy and the number of cores per target.

On the basis of biopsy data alone, it may be methodologically incorrect to conclude that MRI-US fusion biopsy detects more significant prostate cancers compared with systematic biopsy. This conclusion may be a statistical or methodological effect rather than a true clinical fact. All patients would have to undergo radical prostatectomy and assessment of the final pathology to draw clinically relevant conclusions. Such studies are warranted in the future.

In summary, a meta-analysis of the currently available high-level clinical studies was performed to evaluate the efficacy of MRI-US fusion prostate biopsy. It was revealed that MRI-US fusion prostate biopsy has a higher detection rate of prostate cancer compared with systematic biopsy. MRI-US fusion biopsy also detects more clinically significant and fewer insignificant prostate cancers compared with systematic protocols. It is therefore recommended that mp-MRI is performed in patients suspected of having prostate cancer in order to optimize the detection of clinically significant prostate cancer, while reducing the burden of biopsies.

The present study was supported by the National Natural Science Foundation of China (grant no. 81370781).
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###### 

Main characteristics of the studies included in the meta-analysis.

                                                            Population characteristics                                         MRI-TRUS fusion targeted biopsy                                                                                                                                                      
  ------------------------------------------------ -------- ---------------------------- ------ ------------------------------ --------------------------------- ----------------------------- -------------- ------------------- --------------------------------- ----- ------------------- --------------- ----- --------------------------
  Baco *et al* 2015 ([@b29-mco-0-0-906])           RCT      USA                          175    Mean (range), 65 (59--69)      Mean (range), 7.3 (5.5--9.9)      Mean (range), 42 (30--59)     Biopsy naive   Local               TRUS 12 cores                     1.5   UroStation          Transrectal     Yes   Med (range), 2 (1--4)
  Siddiqui *et al* 2015 ([@b30-mco-0-0-906])       Cohort   USA                          1003   Mean ± SD, 62.1±7.5            Med (IQR), 6.7 (4.4--10.7)        Med (IQR), 49 (36--71)        Mixed          NR                  TRUS 12 cores                     3     UroNav              Transrectal     Yes   2
  Borkowetz *et al* 2015 ([@b31-mco-0-0-906])      Cohort   Germany                      263    Med (range), 66 (47--83)       Med (range), 8.3 (0.39--86.57)    Med (range), 50 (12--220)     Mixed          General or spinal   TRUS 12 cores                     3     Biojet              Transperineal   Yes   ≥2
  Sankineni *et al* 2015 ([@b12-mco-0-0-906])      Cohort   USA                          33     Mean (range), 63 (52--76)      Mean (range), 8.4 (1.22--65.20)   Mean (range), 53 (12--125)    Mixed          NR                  TRUS 12 cores                     3     UroNav              Transrectal     NR    NR
  Zhang *et al* 2015 ([@b13-mco-0-0-906])          Cohort   China                        62     Mean ± SD, 68.38±6.57          Mean ± SD, 10.21±5.57             Mean ± SD, 34.05±9.86         Biopsy naive   General             TRUS 12 cores                     3     RVS                 Transrectal     Yes   ≥2
  de Gorski *et al* 2015 ([@b14-mco-0-0-906])      Cohort   France                       232    Mean ± SD, 64±6.4              Mean ± SD, 6.65±1.8               Mean ± SD, 40±24.3            Biopsy naive   NR                  TRUS 12 cores                     1.5   UroStation          Transrectal     No    NR
  Ukimura *et al* 2015 ([@b15-mco-0-0-906])        Cohort   USA                          127    Med, 69                        Med, 5.8                          NR                            Mixed          Local               TRUS 10--12 cores                 3     UroStation          Transrectal     No    ≥1
  Junker *et al* 2015 ([@b16-mco-0-0-906])         Cohort   Australia                    50     Mean ± SD, 63.7±7.9            Mean ± SD, 7.6±4.2                Mean ± SD, 49.2±21.9          Mixed          NR                  TRUS 10 cores                     3     Logiq               Transrectal     Yes   Mean, 3.9
  Shoji *et al* 2015 ([@b17-mco-0-0-906])          Cohort   Japan                        20     Med (range), 70 (52--83)       Med (range), 7.4 (3.54--19.9)     Med (range), 38 (24--68)      Biopsy naive   Spinal              Transperineal 12 cores            1.5   Biojet              Transrectal     Yes   NR
  Salami *et al* 2015 ([@b18-mco-0-0-906])         Cohort   USA                          140    NR                             NR                                NR                            Negative       NR                  TRUS 12 cores                     3     UroNav              Transrectal     Yes   2
  Mozer *et al* 2015 ([@b19-mco-0-0-906])          Cohort   France                       152    Med (IQR), 63.7 (59.3--67.5)   Med (IQR), 6 (5--7.9)             Med (IQR), 38.5 (30--55)      Biopsy naive   NR                  TRUS 12 cores                     1.5   UroStation          Transrectal     No    2 or 3
  Volkin *et al* 2015 ([@b25-mco-0-0-906])         Cohort   USA                          162    Med (range), 63 (44--80)       Med (range), 8.4 (0.3--95.8)      Med (range), 48 (19--187)     Mixed          Local               TRUS 12 cores                     3     NR                  Transrectal     No    ≥2
  Rastinehad *et al* 2014 ([@b20-mco-0-0-906])     Cohort   USA                          105    Mean (range), 65.8 (42--87)    Mean (range), 9.2 (0.6--62)       NR                            Mixed          NR                  TRUS 12 cores                     3     UroNav              Transrectal     Yes   NR
  Sonn *et al* 2014 ([@b26-mco-0-0-906])           Cohort   USA                          105    Med (IQR), 65 (59--70)         Med (IQR), 7.5 (5--11.2)          Med (IQR), 58 (39--82)        Negative       Local               TRUS 12 cores                     3     Artemis             Transrectal     Yes   Mean (range), 4.2 (1--9)
  Wysock *et al* 2014 ([@b27-mco-0-0-906])         Cohort   USA                          125    Med (range), 65 (56.3--71)     Med (range), 5.1 (3.5--7.3)       Med (range), 46 (31--62.5)    Mixed          Local               TRUS 12 cores                     3     Artemis             Transrectal     Yes   2
  Fiard *et al* 2013 ([@b21-mco-0-0-906])          Cohort   France                       20     Med (range), 65 (62--68)       Med (range), 6.3 (5.3--10)        Med (range), 39 (29--49)      Mixed          Local or general    TRUS 12 cores                     3     UroStation          Transrectal     No    2
  Delongchamps *et al* 2013 ([@b23-mco-0-0-906])   Cohort   France                       133    Mean ± SD, 64.5±7.9            Mean ± SD, 9±3.9                  Mean ± SD, 58.3±28.6          Biopsy naive   NR                  TRUS 10--12 cores                 1.5   Koelis              Transrectal     No    ≥2
  Puech *et al* 2013 ([@b24-mco-0-0-906])          Cohort   France                       95     Med (range), 65 (49--76)       Mean ± SD, 10.05±8.8              Mean ± SD, 52±24              Mixed          Local               TRUS 12 cores                     1.5   Virtual Navigator   Transrectal     No    2
  Kuru *et al* 2013 ([@b28-mco-0-0-906])           Cohort   Germany                      347    Med (range), 65.3 (42--82)     Mean (range), 9.85 (0.5--104)     Mean (range), 48.7 (9--108)   Mixed          General             Transperineal 24 cores            3     BiopSee             Transperineal   Yes   Med (range), 4 (2--6)
  Vourganti *et al* 2012 ([@b22-mco-0-0-906])      Cohort   USA                          195    Med (range), 62 (37--80)       Med (range), 9.13 (0.3--103)      Med (range), 56 (16--187)     Negative       Local               TRUS 12 cores                     3     NR                  Transrectal     No    Med (range), 5 (2--14)
  Miyagawa *et al* 2010 ([@b2-mco-0-0-906])        Cohort   Japan                        85     Med (range), 69 (56--84)       Med (range), 9.9 (4.0--34.2)      Med (range), 37.2 (18--141)   Negative       Spinal              TRUS/transperineal 10--11 cores   1.5   RVS                 Transperineal   Yes   Mean, 1.9

PSA, prostate-specific antigen; MRI, magnetic resonance imaging; TRUS, transrectal ultrasound; RCT, randomized controlled trial; med, median; SD, standard deviation; IQR, interquartile range; NR, not reported.

###### 

Quality assessment of the studies included in the meta-analysis.

                                                                                                                     Overall cancer detection (n/total)   Clinically significant cancer detection (n/total)               
  ---------------------------------------------------- ----------- ------------------------------------------------- ------------------------------------ --------------------------------------------------- ----------- -----------
  Baco *et al*, 2015 ([@b29-mco-0-0-906])              Caucasian   Gleason ≥7 or maximum cancer core length ≥5 mm    51/86                                48/89                                               33/86       44/89
  Siddiqui *et al*, 2015 ([@b30-mco-0-0-906])          Caucasian   NR                                                461/1,003                            469/1,003                                           --          --
  Borkowetz *et al*, 2015 ([@b31-mco-0-0-906])         Caucasian   Gleason \>6, or \>2 cores, or \>50% of any core   116/263                              91/263                                              94/263      75/263
  Sankineni *et al*, 2015 ([@b12-mco-0-0-906])         Caucasian   Gleason \>3+4 with 25% biopsy core involvement    24/33                                19/33                                               16/33       13/33
  Zhang *et al*, 2015 ([@b13-mco-0-0-906])             Asian       Gleason ≥3+4 or cancer core length ≥4 mm          27/62                                21/62                                               14/62       5/62
  de Gorski *et al*, 2015 ([@b14-mco-0-0-906])         Caucasian   Gleason ≥3+4 or cancer core length ≥4 mm          126/232                              129/232                                             102/232     91/232
  Ukimura *et al*, 2015 ([@b15-mco-0-0-906])           Caucasian   Gleason ≥3+4 or cancer core length ≥5 mm          78/127                               52/127                                              54/127      29/127
  Junker *et al*, 2015 ([@b16-mco-0-0-906])            Caucasian   NR                                                23/50                                18/50                                               --          --
  Shoji *et al*, 2015 ([@b17-mco-0-0-906])             Asian       NR                                                14/20                                8/20                                                --          --
  Salami *et al*, 2015 ([@b18-mco-0-0-906])            Caucasian   Gleason \>6, or \>2 cores, or \>50% of any core   68/140                               73/140                                              67/140      43/140
  Mozer *et al*, 2015 ([@b19-mco-0-0-906])             Caucasian   Gleason ≥3+4 or cancer core length ≥4 mm          82/152                               86/152                                              66/152      56/152
  Volkin *et al*, 2014 ([@b25-mco-0-0-906])            Caucasian   NR                                                19/42                                18/42                                               --          --
  Rastinehad *et al*, 2014 ([@b20-mco-0-0-906])        Caucasian   Gleason \>6, or \>2 cores, or \>50% of any core   53/105                               51/105                                              47/105      34/105
  Sonn *et al*, 2014 ([@b26-mco-0-0-906])              Caucasian   Gleason ≥3+4 or cancer core length ≥4 mm          24/102                               27/97                                               21/102      15/97
  Wysock *et al*, 2014 ([@b27-mco-0-0-906])            Caucasian   Gleason ≥3+4                                      45/125                               40/125                                              29/125      24/125
  Fiard *et al*, 2013 ([@b21-mco-0-0-906])             Caucasian   Gleason ≥3+4 or total cancer length ≥10 mm        11/20                                10/20                                               10/20       9/20
  Delongchamps *et al*, 2013 ([@b23-mco-0-0-906])      Caucasian   NR                                                45/125                               40/125                                              --          --
  Puech *et al*, 2013 ([@b24-mco-0-0-906])             Caucasian   Gleason ≥3+4 or cancer core length ≥3 mm          66/95                                56/95                                               64/95       49/95
  Kuru *et al*, 2013 ([@b28-mco-0-0-906])              Caucasian   NCCN criteria                                     128/253                              161/253                                             104/253     121/253
  Vourganti *et al*, 2012 ([@b22-mco-0-0-906])         Caucasian   NR                                                56/195                               45/195                                              --          --
  Miyagawa *et al*, 2010 ([@b2-mco-0-0-906])           Asian       NR                                                45/85                                34/85                                               --          --
  Total^[a](#tfn2-mco-0-0-906){ref-type="table-fn"}^                                                                 1,562/3,315                          1,496/3,313                                         721/1,795   608/1,793

Not all studies were designed as paired cohort studies (e.g., Baco et al), resulting in the inequality of case numbers in fusion group and systematic biopsy groups. NR, not reported; NCCN, National Comprehensive Cancer Network; system, systematic.

###### 

Results of subgroup analysis of significant prostate cancer detection.

                                     Heterogeneity           Meta-analysis                          
  ---------------------------- ----- --------------- ------- --------------- ---------------------- -------
  Study design                                                                                      
    Paired cohort              13    50.3            0.02    Random          1.258 (1.100--1.438)   0.001
    Comparative series           1   --              --      --              0.776 (0.552--1.091)   0.145
  Main race                                                                                         
    Caucasian                  13    55.2            0.008   Random          1.198 (1.047--1.370)   0.009
    Asian                        1   --              --      --              2.800 (1.074--7.302)   0.035
  Prior biopsy                                                                                      
    Mixed                        8   59.8            0.015   Random          1.235 (1.023--1.491)   0.028
    Biopsy naive                 4   62.4            0.047   Random          1.101 (0.833--1.457)   0.498
    Previous negative            2     0.0           0.645   Fixed           1.498 (1.141--1.967)   0.004
  Strength of magnetic field                                                                        
    3T                         10    61.5            0.005   Random          1.311 (1.073--1.601)   0.008
    1.5T                         4   51.6            0.102   Random          1.104 (0.914--1.333)   0.307
  Sampling method                                                                                   
    Transrectal                12    40.3            0.072   Random          1.269 (1.104--1.459)   0.001
    Transperineal                2   81.7            0.019   Random          1.029 (0.710--1.492)   0.879

RR, relative risk; CI, confidence interval.

###### 

Results of sensitivity analysis of significant prostate cancer detection.

                                                   Heterogeneity test   Pooled estimate                         
  ------------------------------------------------ -------------------- ----------------- --------------------- ---------
  Kuru *et al* ([@b28-mco-0-0-906]) incorporated   56.7                 0.0350            1.218 (1.060,1.399)   0.005
  Kuru *et al* ([@b28-mco-0-0-906]) excluded       34.8                 0.0162            1.265 (1.119,1.429)   \<0.001

RR, relative risk; CI, confidence interval.
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